CT-IGFBP-4 as a Novel Prognostic Biomarker in Acute Heart Failure

21 Aug, 2020


no comments

In a recent article, researchers at HyTest, Ltd. continued to study the prognostic value of insulin-like growth factor binding protein-4 (IGFBP-4) fragments in cardiac related diseases. The goal of the study was to assess the carboxy-terminal fragment (CT-IGFBP4) for the prognosis of outcomes of patients with acute heart failure. Read below:


The study showed that CT-IGFBP-4 was independently associated with all-cause mortality in patients with acute heart failure. Compared with single biomarkers, the combination of CT-IGFBP-4, NT-proBNP, and CRP improved the prediction of all-cause mortality in these patients.

For Assay Development and References, see our pdf below:


Advanced ImmunoChemical is open and business continues as normal.

We confirm that we are continuing to supply our products as normal and do not foresee any significant disruption in product availability or ship schedules. However, circumstances can change. Please know we will continue to follow developments and do our best to advise you as soon as possible if the situation regarding our product supply changes.

Browse our website and order online: AdvImmuno.com/Shop

If you are interested in receiving further information or have other questions, please contact us by e-mail at info@advimmuno.com.

Skip to toolbar